Nabla Bio
Antibody drugs that are more likely to get approved
S20ActiveAI-powered Drug Discovery
Antibody drugs that are more likely to get approved
At Nabla, we’ve developed a protein engineering platform that makes it easier to design antibodies that are more likely to get FDA approved. We do this by learning the molecular properties that differentiate approved antibodies from ones that have failed.
Nabla Bio
Founded:2020
Team Size:5
Location:Boston
Active Founders
Frances Anastassacos
Currently building Nabla Bio! I've spent the last 8 years applying my chemistry training to problems in biology and specifically synthetic biology. I did my PhD at Harvard (Class 2019, BBS) and spent some time in biotech VC.
Frances Anastassacos
Nabla BioSurge Biswas
Currently building Nabla Bio. I'm a scientist with 10+ years of experience with using synthetic biology and machine learning to engineer everything from the microbiome to proteins. I recently completed my PhD from George Church's lab at Harvard.
